The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients

The efficacy of sodium-dependent glucose co-transporter 2(SGLT2) inhibitors for pericardial fat in the type 2 diabetes patients - The efficacy of SGLT2 inhibitors for pericardial fat in the type 2 diabetes patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020200

Enrollment

Registered

2015-12-15

Start date

2015-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes patients with pericardial fat is more than 125 ml

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who obtained the start or switching of consent the dapagliflozin of SGLT2 inhibitors. 2) Patients with pericardial fat is more than 125ml in coronary CT angiography. 3) Patient age of 20 years or older at the time of obtaining informed consent. 4) Patients who themselves can voluntarily provide consent to participate in this study, and can also follow the study protocol.

Exclusion criteria

Exclusion criteria: 1)Patients with decreased renal function. 2)Patient corresponding to the contraindications and careful administration of SGLT2 inhibitors. 3)Patients research investigator has determined to be inappropriate as a patient.

Design outcomes

Primary

Measure	Time frame
We administered the dapagliflozin to the patient, and observe the changes in the CT value of the amount and pericardial fat.	—

Secondary

Measure	Time frame
We will observe changes in the subjective symptoms, objective findings, and clinical examination (blood biochemistry, electrocardiogram, ABI). In addition, we will evaluate the safety of such adverse events.	—

Countries

Japan

Contacts

Public ContactTakehito Shizuka

National Hospital Organization Takasaki General Medical Center Division of Cardiology

tshizuka8@gmail.com027-322-5901

Outcome results